Skip to main content

Publisher: Elsevier

Volume 20, Supplement 3, August 1999

Antiviral treatments and hepatitis C virus infection
pp. 331s-340s(10)
Author: Silvain, C.

Favourites:
ADD
Favourites:
ADD

New therapeutic strategies in multiple sclerosis
pp. 346s-350s(5)
Authors: Berger, E.; Rumbach, L.

Favourites:
ADD

Update in the treatment of type 2 diabetes mellitus. Insulin secreting agents
pp. 351s-359s(9)
Authors: Blickle, J.F.; Andres, E.; Neyrolles, N.; Brogard, J.M.

Favourites:
ADD

Dietary and drug therapies for primary prevention of atherosclerosis
pp. 360s-370s(11)
Authors: Monnier, L.; Avignon, A.; Colette, C.; Piperno, M.

Favourites:
ADD

Update in the treatment of type 2 diabetes mellitus. The spring of insulin-sensitizers
pp. 371s-378s(8)
Authors: Brogard, J.M.; Neyrolles, N.; Andres, E.; Blickle, J.F.

Favourites:
ADD

Update in the treatment of type 2 diabetes mellitus. The α-glucosidase inhibitors
pp. 379s-383s(5)
Authors: Blickle, J.F.; Andres, E.; Brogard, J.M.

Favourites:
ADD

Methotrexate and dermatology: pharmacology, indication and practical use
pp. 384s-392s(9)
Authors: Lebrun-Vignes, B.; Bachelez, H.; Chosidow, O.

Favourites:
ADD

A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
pp. 393s-398s(6)
Authors: Sasaki, J.; Arakawa, K.; Yamamoto, K.; Kobori, S.; Ageta, M.; Kono, S.

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more